about
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysisImproved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trialTreatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints.Atrial fibrillation in a large population with Brugada electrocardiographic pattern: prevalence, management, and correlation with prognosis.International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences.Are propensity scores really superior to standard multivariable analysis?Use and misuse of multivariable approaches in interventional cardiology studies on drug-eluting stents: a systematic review.Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.Meta-analysis of the usefulness of Mitraclip in patients with functional mitral regurgitation.Illustrated Atlas of Post-AF Ablation Cerebral Abnormalities.Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation.Cryptogenic ischemic stroke and prevalence of asymptomatic atrial fibrillation: a prospective study.Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis.Meta-analysis of coronary CT angiography in the emergency department: reply.The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.Simplifying clinical risk prediction for percutaneous coronary intervention of bifurcation lesions: the case for the ACEF (age, creatinine, ejection fraction) score.Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.Selective Vulnerability of Cortical Border Zone to Microembolic Infarct.Spinal cord stimulation for the treatment of refractory angina pectoris: a multicenter randomized single-blind study (the SCS-ITA trial).Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II).The heart in an airbag: spontaneous pneumopericardium in a young lady.Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart FailureReply to the letter by Dr Erqou regarding “Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients”Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failureAtherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: A meta-regression of randomized clinical trialsIncidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thrombosesSpinal cord stimulation affects T-wave alternans in patients with ischaemic cardiomyopathy: a pilot studyHistologically benign but clinically malignant: an unusual case of recurrent atrial myxomaCan spinal cord stimulation reduce ventricular arrhythmias?Clinical, electrocardiographic, echocardiographic characteristics and long-term follow-up of elite soccer players with J-point elevationLong-term progression from paroxysmal to permanent atrial fibrillation following transcatheter ablation in a large single-center experience
P50
Q26824136-A89125B4-FC5F-4E14-8D8C-45B42ECD42F8Q28085643-DF74AE67-86B1-4D0C-B368-E43A531E7598Q28278243-1A5D9D19-C5C4-4B87-9DD6-C48A89BCEC8FQ30842662-BB2FDD3A-3407-4FAF-9C22-043EF85D97FFQ33163804-8EFBD6FB-67C9-48D0-977C-512BD34E9860Q37799119-81571350-2432-49DA-ACC3-25D7E3A7B86CQ37880361-7A87EEB9-DF09-42AA-9996-A115E44504BEQ38033691-711A051B-B733-408E-82E8-B8E34B64BD02Q38074639-40BB743C-CD38-40FA-B357-A6E757C83325Q38480767-7EB4CBF3-16F0-4AB3-A1EA-7FFBD6F3F90FQ38804137-3361277E-92E1-4419-9513-4769FFB08433Q39267912-06C7C78C-18EE-43B2-9970-F3539473F793Q40516501-091F3B12-4C0C-4630-BD54-178BC52B59E2Q41376656-20FF4431-FDFE-4C13-9CCB-DD4A46ACC2ECQ43521281-6F117790-1068-4A93-B35C-2077B40698DCQ44694136-DFD6BBA1-1856-40AD-9FAA-BA502207AEC7Q44971239-6ECCBA50-5C1F-4AE5-AEAB-DCA19F182B60Q45083522-302C4E5A-1B11-4C0F-8BC4-08AE5DCCCD3DQ45954011-4062703F-A931-434F-815B-6B8A80319D47Q48135717-B0723811-0A2F-4B79-ACFC-97F9379E547AQ48758673-F783A350-5479-41A4-ABCD-2A9B7308AE4DQ51816484-36991CD3-A065-4793-88DF-A71602A053E1Q53203940-50D463FA-C88D-4114-9C22-D21ACD683299Q57396205-2485C159-3EA4-44B0-995C-87A85C59CC4BQ57396216-0F452C68-F2A5-4521-8027-71BDCFA7CB79Q57396218-7934507B-ED49-4046-B709-595B5EC22AADQ57730866-20EB63F6-567A-45A7-B59E-2693FFA4CB1EQ58492041-8B695B24-4C11-46D7-A917-654F3EF578C7Q80868909-8468B221-C402-4D4B-A3F9-CDA8BEB66956Q83039541-F3126789-6425-42CE-A2D9-CBD72DCCCB27Q84760954-12138ED1-ABB0-4031-B6CC-DF99498EB14BQ86478711-BED0D95F-7FE8-40DC-9F19-E8CC058445E5Q87342759-A769ECA8-0F60-43C2-9EBA-CB94F4537ED5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Davide Castagno
@ast
Davide Castagno
@en
Davide Castagno
@es
Davide Castagno
@nl
Davide Castagno
@sl
type
label
Davide Castagno
@ast
Davide Castagno
@en
Davide Castagno
@es
Davide Castagno
@nl
Davide Castagno
@sl
prefLabel
Davide Castagno
@ast
Davide Castagno
@en
Davide Castagno
@es
Davide Castagno
@nl
Davide Castagno
@sl
P106
P1153
24281355100
P31
P496
0000-0001-8491-152X